Clinical Advisory Board
Felix Ratjen , MD, FRCP(C)Dr. Ratjen is the Division Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Paediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine. He is co-leader of the Cystic Fibrosis centre at SickKids and Medical Director of the Clinical Research Unit. Dr. Ratjen has conducted multiple clinical trials addressing cystic fibrosis lung disease including new therapeutic strategies, treatment of airway infections, airway inflammation and other important aspects of the disease. |
Michael Konstan, M.DDr. Konstan is the Chairman of the Department of Pediatrics of Case Western Reserve University (CWRU) School of Medicine. In addition, he is the director of The LeRoy W. Matthews Cystic Fibrosis Center at Rainbow Babies and Children’s Hospital. Dr. Konstan’s academic career has focused on developing new therapies for the lung disease of cystic fibrosis (CF), with a special interest in anti-inflammatory therapies and clinical trial design. He has led numerous national and international CF trials of potentially new therapies for Cystic Fibrosis, and is regarded as a national and international expert in this disease. |
Elliott C. Dasenbrook, MD MHSDr. Dasenbrook is Assistant Professor of Medicine and Associate Director of the Adult Cystic Fibrosis Program at Case Western Reserve University (CWRU) School of Medicine. He is a leading researcher on the effects of MRSA in Cystic Fibrosis patients. Dr. Dasenbrook co-authored a ground breaking study in 2010 that showed the impact on survival is a life span that is a median 6.2 years shorter in CF patients with MRSA than those without. |
Michael Patrick Boyle, M.D., F.C.C.P.Dr. Boyle is Director of the Adult Cystic Fibrosis Program at Johns Hopkins. He is board certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine. His awards include the Clinical Research Award and the Shwachman Award, both from the Cystic Fibrosis Foundation. |
Grant Waterer, MBBSDr. Waterer is Head of Unit/Professor at the School of Medicine and Pharmacology Royal Perth Hospital Unit at the University of Western Australia. He is a respiratory specialist seeing general respiratory diseases but with a particular interest in pulmonary infectious diseases. |
Taneli Jouhikainen, MD, PhD, MBADr. Jouhikainen is COO of Savara Pharmaceuticals. |